Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 14,205 shares of Common Stock at $69.75 per share. The transaction occurred on May 29, 2026 and was executed under a pre-established Rule 10b5-1 trading plan adopted on May 7, 2025.
After this sale, Cho directly holds 120,094 Twist Bioscience shares, indicating the transaction represents only a portion of his overall ownership. Because the trade was made pursuant to a Rule 10b5-1 plan, its timing reflects a pre-planned arrangement rather than a discretionary decision based on near-term company developments.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of common stock. On May 29, 2026, he sold 4,000 shares at a price of $70.00 per share. After the transaction, he directly holds 112,675 common shares. The sale was executed under a previously adopted Rule 10b5-1 trading plan dated May 8, 2025, indicating the trades were pre-scheduled rather than timed at his discretion.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a combination of option exercise and share sales in common stock. She exercised employee stock options to acquire 16,470 shares at an exercise price of $8.82 per share, then sold 16,470 shares in multiple open‑market transactions at prices ranging from $65.3256 to $68.6141 per share. After these transactions, she directly owns 861,860 shares of Twist common stock. The sales were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on May 27, 2025.
Twist Bioscience Corp director Melissa A. Starovasnik sold 2,500 shares of Common Stock in an open-market transaction at $68.00 per share. The trade took place on May 28, 2026 and was reported as a direct ownership transaction.
Following this sale, she directly holds 22,222 shares of Twist Bioscience Corp. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the sale was scheduled in advance.
TWST submitted a Form 144 notice reporting proposed sales of Common Stock by an affiliate. The excerpt lists four recent sale entries: 425 shares on 03/06/2026, 354 shares on 03/20/2026, 1,962 shares on 05/04/2026, and 1,642 shares on 05/21/2026, each with the dollar amounts shown. The filing also lists routine issuer grant and ESPP vesting events dated 2022–2024.
TWST filed a Form 144 reporting proposed and recent dispositions of Common Stock by an affiliated party. The filing lists scheduled restricted stock vesting events on 07/08/2025, 08/20/2025, and 05/20/2026 totaling 4,000 shares in one line item and additional individual grants of 1,716; 592; and 1,692 shares. The filing also reports four recent sales by Adam Laponis: 2,597 shares on 04/09/2026, 3,000 shares on 04/14/2026, 4,000 shares on 04/17/2026, and 2,019 shares on 05/21/2026, with dollar amounts shown for each transaction.
Twist Bioscience Corporation reported insider resale activity via Form 144 indicating sales of common stock by Emily M. Leproust on multiple dates in 2026. The filing lists individual block dispositions with cash proceeds for each sale and notes an option-related sale dated 05/28/2026 tied to an option granted 09/29/2017.
Twist Bioscience Corp director Melissa A. Starovasnik sold 500 shares of Common Stock in an open-market transaction. The sale occurred on May 26, 2026 at a price of $61.04 per share. After this transaction, she continues to hold 24,722 shares directly. The company notes that this trade was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary market-timing decision.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an exercise-and-sell transaction under a pre-arranged Rule 10b5-1 trading plan. She exercised options to acquire a total of 49,299 shares of common stock at an exercise price of $8.82 per share and sold the same number of shares in open-market transactions.
The sales covered 24,282 shares at a weighted average price of $65.0789 per share, 23,752 shares at $65.2392 per share, and 1,265 shares at $66.2813 per share. After these transactions, she continues to hold 846,872 shares of Twist Bioscience common stock directly, along with remaining employee stock options, including awards exercisable into 64,950 shares at an exercise price of $67.85 per share.
Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported a small mandated stock sale to cover taxes. On the transaction date, he sold 800 shares of common stock in an open-market transaction at an average price of $62.484 per share.
According to the footnote, this sale was required to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After this sale, Werner directly holds 48,186 shares of Twist Bioscience common stock.